References

1. 1..
   Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR,et al. Global, regional, and national sepsis incidence and mortality,1990-2017: analysis for the global burden of disease study. Lancet. 2020;395(10219):200–11.
2. 2..
   Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330(6149):662–4.
3. 3..
   Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J,et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248–51.
4. 4..
   Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A. 2004;101(1):296–301.
5. 5..
   Zhu CS, Qiang X, Chen W, Li J, Lan X, Yang H, et al. Identification of procathepsin L (pCTS-L)-neutralizing monoclonal antibodies to treat potentially lethal sepsis. Sci Adv. 2023;9(5): eadf4313.
6. 6..
   Li J, Zhu CS, He L, Qiang X, Chen W, Wang H. A two-decade journey in identifying high mobility group box 1 (HMGB1) and procathepsin L(pCTS-L) as potential therapeutic targets for sepsis. Expert Opin Ther Targets. 2023;27(7):575–91.
7. 7..
   Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019–33.
8. 8..
   McInnes IB, Schett G. Pathogenetic insights from the treatment of rheu-matoid arthritis. Lancet. 2017;389(10086):2328–37.
9. 9..
   Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 2003;48(7):2052–8.
10. 10..
    Yang H, Zeng Q, Silverman HA, Gunasekaran M, George SJ, Devarajan A,et al. HMGB1 released from nociceptors mediates inflammation. Proc Natl Acad Sci U S A. 2021. .
11. 11..
    Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338–48.
12. 12..
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344(8930):1105–10.
13. 13..
    Wang H, Ayala A, Aziz M, Billiar TR, Deutschman CS, Jeyaseelan S, et al. Value of animal sepsis research in navigating the translational labyrinth. Front Immunol. 2025;16:1593342.
14. 14..
    Yang H, Wang H, Ju Z, Ragab AA, Lundback P, Long W, et al. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med. 2015;212(1):5–14.
15. 15..
    Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, et al. HMGB1 sig-nals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006;26(2):174–9.
16. 16..
    Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is medi-ated by HMGB1 and RAGE. Nat Immunol. 2007;8(5):487–96.
17. 17..
    Xu J, Jiang Y, Wang J, Shi X, Liu Q, Liu Z, et al. Macrophage endocytosis of high-mobility group box 1 triggers pyroptosis. Cell Death Differ. 2014;21(8):1229–39.
18. 18..
    Deng M, Tang Y, Li W, Wang X, Zhang R, Zhang X, et al. The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis. Immunity. 2018;49(4):740–53.
19. 19..
    Yang H, Wang H, Levine YA, Gunasekaran MK, Wang Y, Addorisio M, et al. Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes. JCI Insight. 2016;1(7): e85375.
20. 20..
    Son M, Porat A, He M, Suurmond J, Santiago-Schwarz F, Andersson U,et al. C1q and HMGB1 reciprocally regulate human macrophage polariza-tion. Blood. 2016;128(18):2218–28.
21. 21..
    Chen W, Qiang X, Wang Y, Zhu S, Li J, Babaev A, et al. Identification of tetranectin-targeting monoclonal antibodies to treat potentially lethal sepsis. Sci Transl Med. 2020;12(539):12/539.
22. 22..
    Lemaire R, Huet G, Zerimech F, Grard G, Fontaine C, Duquesnoy B, et al. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br J Rheumatol. 1997;36(7):735–43.
23. 23..
    Gerber A, Wille A, Welte T, Ansorge S, Buhling F. Interleukin-6 and trans-forming growth factor-beta 1 control expression of cathepsins B and L in human lung epithelial cells. J Interferon Cytokine Res. 2001;21(1):11–9.
24. 24..
    Chen W, Zhu CS, Qiang X, Chen S, Li J, Wang P, et al. Development of pro-cathepsin L (pCTS-L)-inhibiting lanosterol-carrying liposome nanoparti-cles to treat lethal sepsis. Int J Mol Sci. 2023;24(10):8649.
25. 25..
    Qiang X, Chen W, Zhu CS, Li J, Qi T, Lou L, et al. Therapeutic potential of procathepsin L-inhibiting and progesterone-entrapping dimethyl-β-cyclodextrin nanoparticles in treating experimental sepsis. Front Immunol. 2024;15:1368448.
26. 26..
    Yang S, Chen K, Yu J, Jin Z, Zhang M, Li Z, et al. Inhibition of cathepsin L ameliorates inflammation through the A20/NF-κB pathway in endotoxin-induced acute lung injury. iScience. 2024;27(11):111024.
27. 27..
    Ikeda Y, Ikata T, Mishiro T, Nakano S, Ikebe M, Yasuoka S. Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase. J Med Invest. 2000;47(1–2):61–75.
28. 28..
    Ruge T, Södergren A, Wållberg-Jonsson S, Larsson A, Arnlöv J. Circulat-ing plasma levels of cathepsin S and L are not associated with disease severity in patients with rheumatoid arthritis. Scand J Rheumatol. 2014;43(5):371–3.
29. 29..
    Weitoft T, Larsson A, Manivel VA, Lysholm J, Knight A, Rönnelid J. Cathepsin S and cathepsin L in serum and synovial fluid in rheumatoid arthritis with and without autoantibodies. Rheumatology (Oxford). 2015;54(10):1923–8.
30. 30..
    Keyszer GM, Heer AH, Kriegsmann J, Geiler T, Trabandt A, Keysser M, et al. Comparative analysis of cathepsin L, cathepsin D, and collagenase mes-senger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization. Arthritis Rheum. 1995;38(7):976–84.
31. 31..
    Iwata Y, Mort JS, Tateishi H, Lee ER. Macrophage cathepsin L, a factor in the erosion of subchondral bone in rheumatoid arthritis. Arthritis Rheum. 1997;40(3):499–509.
32. 32..
    Schurigt U, Eilenstein R, Gajda M, Leipner C, Sevenich L, Reinheckel T, et al. Decreased arthritis severity in cathepsin L-deficient mice is attributed to an impaired T helper cell compartment. Inflamm Res. 2012;61(9):1021–9.
33. 33..
    Schedel J, Seemayer CA, Pap T, Neidhart M, Kuchen S, Michel BA, et al. Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. Gene Ther. 2004;11(13):1040–7.
34. 34..
    Jensen BA, McNair P, Hyldstrup L, Clemmensen I. Plasma tetranectin in healthy male and female individuals, measured by enzyme-linked immu-nosorbent assay. J Lab Clin Med. 1987;110(5):612–7.
35. 35..
    McDonald K, Glezeva N, Collier P, O’Reilly J, O’Connell E, Tea I, et al. Tetranectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis. Sci Rep. 2020;10(1):7507.
36. 36..
    Kopeva KV, Grakova EV, Shilov SN, Berezikova EN, Bobyleva ET, Teplyakov AT. Tetranectin as a potential novel prognostic biomarker in anthracy-cline-related cardiac dysfunction. Heart Vessels. 2023;38(10):1256–66.
37. 37..
    Kamper EF, Kopeikina LT, Trontzas P, Kyriazis NC, Vaiopoulos G, Stavridis J. Comparative study of tetranectin levels in serum and synovial fluid of patients with rheumatoid arthritis, seronegative spondylarthritis and osteoarthritis. Clin Rheumatol. 1998;17(4):318–24.
38. 38..
    Lorentsen RH, Graversen JH, Caterer NR, Thogersen HC, Etzerodt M. The heparin-binding site in tetranectin is located in the N-terminal region and binding does not involve the carbohydrate recognition domain. Biochem J. 2000;347(Pt 1):83–7.
39. 39..
    Graversen JH, Lorentsen RH, Jacobsen C, Moestrup SK, Sigurskjold BW, Thogersen HC, et al. The plasminogen binding site of the C-type lectin tetranectin is located in the carbohydrate recognition domain,and binding is sensitive to both calcium and lysine. J Biol Chem. 1998;273(44):29241–6.
40. 40..
    Westergaard UB, Andersen MH, Heegaard CW, Fedosov SN, Petersen TE. Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator. Eur J Biochem. 2003;270(8):1850–4.
41. 41..
    Paterson CW, Ford ML, Coopersmith CM. Breaking the bond between tetranectin and HMGB1 in sepsis. Sci Transl Med. 2020;12(539):12/539.
42. 42..
    Lewis MJ. Predicting best treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2024;64s:152329.
43. 43..
    Atzeni F, Nucera V, Gerratana E, Cirillo M, Marino F, Miceli G, et al. Concerns about the safety of anti-TNF agents when treating rheumatic diseases. Expert Opin Drug Saf. 2020;19(6):695–705.
44. 44..
    Rubbert-Roth A, Szabó MZ, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun Rev. 2019;18(12):102398.
45. 45..
    Prado MS, Bendtzen K, Andrade LEC. Biological anti-TNF drugs: immuno-genicity underlying treatment failure and adverse events. Expert Opin Drug Metab Toxicol. 2017;13(9):985–95.
46. 46..
    Osuchowski MF, Ayala A, Bahrami S, Bauer M, Boros M, Cavaillon JM, et al. Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): an international expert consensus initiative for improvement of animal mod-eling in sepsis. Shock. 2018;50(4):377–80.
47. 47..
    Zingarelli B, Coopersmith CM, Drechsler S, Efron P, Marshall JC, Moldawer L, et al. Part I: Minimum quality threshold in preclinical sepsis studies(MQTiPSS) for study design and humane modeling endpoints. Shock. 2019;51(1):10–22.
48. 48..
    Chen W, Brenner M, Aziz M, Chavan SS, Deutschman CS, Diamond B,et al. Buprenorphine markedly elevates a panel of surrogate markers in a murine model of sepsis. Shock. 2019;52(5):550–3.
49. 49..
    Cotroneo TM, Hugunin KM, Shuster KA, Hwang HJ, Kakaraparthi BN, Nemzek-Hamlin JA. Effects of buprenorphine on a cecal liga-tion and puncture model in C57BL/6 mice. J Am Assoc Lab Anim Sci. 2012;51(3):357–65.
50. 50..
    Hayer S, Vervoordeldonk MJ, Denis MC, Armaka M, Hoffmann M, Bäcklund J, et al. Smash recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal mod-els. Ann Rheum Dis. 2021;80(6):714–26.
51. 51..
    Zhu S, Ashok M, Li J, Li W, Yang H, Wang P, et al. Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory mark-ers. Mol Med. 2009;15(7–8):275–82.
52. 52..
    Zhu SC, Li J, Wang H. Use of open surface plasma resonance (OpenSPR) to characterize teh binding affinity of protein-protein interactions. Bio-Protoc. 2023;13(17): e4795.
53. 53..
    Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5(4):725–38.
54. 54..
    Li W, Bao G, Chen W, Qiang X, Zhu S, Wang S, et al. Connexin 43 hemichannel as a novel mediator of sterile and infectious inflammatory diseases. Sci Rep. 2018;8(1):166–18452.
55. 55..
    Chen W, Zhu S, Wang Y, Li J, Qiang X, Zhao X, et al. Enhanced macrophage pannexin 1 expression and hemichannel activation exacerbates lethal experimental sepsis. Sci Rep. 2019;9(1):160–37232.
56. 56..
    Costanza B, Turtoi A, Bellahcène A, Hirano T, Peulen O, Blomme A, et al. Innovative methodology for the identification of soluble biomarkers in fresh tissues. Oncotarget. 2018;9(12):10665–80.
57. 57..
    Heuer JG, Sharma GR, Gerlitz B, Zhang T, Bailey DL, Ding C, et al. Evalu-ation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis. Crit Care Med. 2004;32(7):1570–8.
58. 58..
    Li W, Ashok M, Li J, Yang H, Sama AE, Wang H. A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One. 2007;2(11): e1153.
59. 59..
    Sakkas LI, Bogdanos DP. Infections as a cause of autoimmune rheumatic diseases. Autoimmun Highlights. 2016;7(1):13.
60. 60..
    Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A. 2010;107(26):11942–7.
61. 61..
    Tang D, Kang R, Zeh HJ, Lotze MT. The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol. 2023;23(12):824–41.
62. 62..
    Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;192(4):565–70.
63. 63..
    Etherington DJ, Taylor MA, Henderson B. Elevation of cathepsin L levels in the synovial lining of rabbits with antigen-induced arthritis. Br J Exp Pathol. 1988;69(2):281–9.
64. 64..
    JrStone CA., Spiller BW, Smith SA. Engineering therapeutic monoclonal antibodies. J Allergy Clin Immunol. 2024;153(3):539–48.
65. 65..
    Al Shoyaib A, Archie SR, Karamyan VT. Intraperitoneal route of drug administration: should it be used in experimental animal studies?. Pharm Res. 2019;37(1):12.
66. 66..
    Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med. 2006;203(7):1637–42.
67. 67..
    Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med. 2004;10(11):1216–21.